Summary.-The tumour specific transplantation antigen (TSTA) from a chemically induced rat sarcoma has been isolated as an electrophoretically homogeneous soluble material by affinity chromatography using a Sepharose bound antibody raised to the tumour in syngeneic rats. The TSTA is specific for the particular tumour used (the MC-1 sarcoma) and does not cross-react with material extracted from other rat sarcomata. In addition, a material with different physicochemical properties which cross-reacted with different sarcomata was also eluted from the antibody column and this may be the previously identified onco-embryonic antigen (OEAl) which is immunogenic in the syngeneic host.
THE EXISTENCE of individually unique tumour specific transplantation antigens (TSTA) has been demonstrated in the membranes of chemically induced sarcomata of experimental animals by in vivo transplantation methods and by in vitro tests (Old and Boyse, 1964; Baldwin and Barker, 1967; Hellstrom and Hellstr6m, 1969) . Recently, TSTA solubilization has been achieved either by limited papain digestion or by hypertonic salt extraction and the antigenic components isolated from any one tumour by various procedures are, in general, heterogeneous as measured by polyacrylamide gel electrophoresis (Holmes, Kahan and Morton, 1970; Meltzer et al., 1971; Baldwin and Glaves, 1972; Thomson and Alexander, 1973a) . We describe here the direct purification of such solubilized TSTA obtained from isolated tumour cell membranes by affinity chromatography, using syngeneic antiserum directed against the tumour. Antibodies directed to the TSTA of transplantable sarcomata are found in the sera of syngeneic rats following surgical excision of the tumour and hyperimmunization with tumour cells (Thomson, Steel and Alexander, 1973b) . Such sera also contain an antibody which reacts against another tumour associated membrane antigen which, unlike the TSTA, is not unique to individual sarcomata but is found in most rat sarcomata and also in the tissues from early embryos. For this reason this material has been called " oncoembryonic antigen " (OEA1) (Thomson and Alexander, 1973a) . In addition, the sera from rats frequently carry autoantibodies to normal tissue components (Weir and Elson, 1969) , but these can be removed by absorption with homogenates from normal rat cells. Contamination with OEA1 or normal * M.R.C. Scholar, the Montreal General Hospital, University Medical Clinic, Montreal, Canada. tissue antigens of the material eluted from syngeneic antisera to the MC-1 rat sarcoma was avoided by taking suitable precautions. A particular advantage of the method described here is that the Sepharose linked tumour immune yglobulin employed for the isolation of the TSTA is also used for the radioimmunoassay of the TSTA, in which the soluble TSTA isolated by affinity chromatography and then labelled with 1251 is used as antigen.
MATERIALS AND METHODS
Tumours used.-A 20-methylcholanthrene induced sarcoma carried in syngeneic male hooded rats and designated MC-1 was used in its early transplant generations. The MC-1 tumour is highly immunogenic and does not cross-react with other chemically induced sarcomata when assessed by transplantation tests (Thomson and Alexander, 1973a; Thomson et al., 1973b) . To check the specificity of the TSTA isolates from the MC-1 tumour another 20-methylcholanthrene induced syngeneic hooded rat sarcoma designated MC-3 was used.
Anti-serum.-Immune serum to the MC-1 tumour was raised by inoculating syngeneic male rats with tumour cells intramuscularly and surgically excising the resulting tumour 2 weeks later. These rats then received repeated injections at multiple sites of irradiated tumour cells (15,000 rad) over a period of 3 months. y-globulins from immune sera were partially purified by 40% ammonium sulphate precipitation. Similar antisera were raised to 2 unrelated transplanted methylcholanthrene induced sarcomata which were also syngeneic in male hooded rats and these tumours were designated MC-9 and MG-Il.
Removal of autoimmune antibodies in syngeneic tumour immune serum by absorption.-Soluble proteins from the 3 mol/l KCG extraction of a pool of normal rat organs were cross-linked with glutaraldehyde as previously described (Thomson et al., 1973b; Avrameas and Ternynck, 1969) . The solid immunoabsorbent obtained was employed in a batch-wise technique to absorb autoantibodies from the syngeneic y-globulins of MC-1 tumour immune serum.
Solubilization and labelling of antigen.-Water soluble antigens were prepared from the MC-1 tumour and to serve as a control from the MC-3 tumour either by digesting crude membrane material with papain or extracting solid tumour after gentle homogenization with 3 mol/l KCG. Both these procedures have been described previously (Thomson and Alexander, 1973a) . Extracts were labelled with 125I by the method of Greenwood, Hunter and Glover (1963) using chloramine T.
Gel chromatography.-The solubilized extract of tumour was applied to a Biogel A 0 5 mol/l (Biorad Laboratories Ltd.) column (4 x 55 cm) and eluted at 4°C with buffer consisting of 0 3 mol/l glycine, 0-1 mol/l Tris, 0-2 mol/l NaCl, 1 mmol/l EDTA, pH 8-0 by upward flow. Fractions eluted from the column were pooled into 5 separate fractions, concentrated against Aquacide 11 (Calbiochem) to approximately 8 ml and dialysed against PBS (phosphate buffered saline, pH 7.3).
Polyacrylamide gel electrophoresis (PAGE). -A slightly modified version of the original procedure described by Davis (1964) was employed using 5 mm x 70 mm tubes for the gels which were made up with 7.5% (w/v) acrylamide and 0-2 % methylene-bis-acrylamide in a 0 4 mol/l Tris-HCl buffer at pH 8-9 and cross-linked with ammonium persulphate. Samples of 20 ,lI of 125I labelled antigen (0-15 mol/l NaCl, 0.01 mol/l Trisglycine, pH 7.6) were preincubated with 30 pl of y-globulin or buffer alone and then mixed with 20 ,ul of 20% sucrose and bromophenol blue. These solutions were layered carefully on the gel surfaces and electrophoresis was carried out at 2°C using a pulsed constant power supply (Ortec). Gels were sectioned at 1i5 mm intervals.
Separation by affinity chromatography with Sepharose coupled antibody.-The y-globulin fraction from syngeneic MC-1 immune serum isolated by ammonium sulphate precipitation was linked covalently to cyanogen bromide activated Sepharose 4B in a 0-2 mol/l pH 6-5, citrate buffer by the method of Cuatrecasas (1970 Serum w%as obtained from normal, MC-1 and unrelated tumour bearers and stored at -20°C. All serum and lymph samples were fractionated with pH 3-1 glycine-HCl on an Amicon XM-100 membrane as previously described (Thomson et al., 1973b ) and the molecular weight fraction less than 100,000 daltons, the " antigen fraction ", was tested for TSTA activity. All samples were assayed in duplicate and frequently the assay was repeated. 0-3 ml of the " antigen fraction" derived from 2 ml of a serum or 5 ml of a lymph sample were assayed. Thoracic duct cannulation, collection and preparation of lymph were as previously described (Thomson, Eccles and Alexander 1973c) .
RESULTS

Preliminary purification by gel exclusion chromatogr-aphy
The material solubilized by either papain treatment or KCI extraction of membranes from the MC-1 sarcoma was chromatographed on Biogel AO5 m. The eluate was pooled into 5 fractions which covered different molecular size ranges. F. 1 contains the higher molecular weight substances which are excluded by the gel and the other 4 fractions are the included materials of relatively lower molecular weight, fraction F5 containing substances of the lowest molecular weight range studied. The eluate patterns have been published previously (Thomson and Alexander, 1973a from the MC-3 tumour and eluted off the solid phase coupled anti-y-globulin to the MC-I tumour had a principal peak at 0-68 but this material (see Table) does not contain TSTA activity. These experiments suggest that the material which moves on PAGE with a relative mobility of 0-68 is not the TSTA.
The eluates obtained from the coupled y-globulin after applying tumour extracts may contain not only tumour specific substances which are antigenic in the syngeneic host (i.e. TSTA or OEAI) but also normal cell constituents, to which the rat had developed autoantibodies (Weir and Elson, 1969) . To eliminate the presence of the latter, the yglobulin isolated from the syngeneic antiserum to the MC-1 tumour was absorbed by normal rat tissue before being used for affinity chromatography. Fig. lc and Id show the patterns on PAGE of eluates from the absorbed y-globulin using as a starting material fraction 5 of a MC-1 papain-solubilized extract which contains the TSTA activity. Fig. lc shows that a sharply defined peak was obtained with a relative mobility of 0.36. Incubation of the 125I labelled proteins with normal rat y-globulin did not alter the position of the peak. To demonstrate that this peak was related to the TSTA which is unique to the MC-1 sarcoma, and not shared by other sarcomata syngeneic to the same hooded strain of rats, the eluate from the MC-1 tumour (F5 fraction) was incubated with y-globulin either from syngeneic antiserum to the MC-1 tumour or a mixture from syngeneic antisera to 2 other hooded rat sarcomata. Fig. Id shows that after addition of the MC-1 serum, material moved much more slowly and the original peak at 0-36 relative mobility was totally obliterated. On the other hand, the y-globulin to the other tumours had no Affinity chromatography isolates of a 3 mol/l KCI extract of an unrelated MC-3 tumour gave no significant inhibition (Fig. 2) . Normal, MC-1 and unrelated sera from tumour bearers were fractionated with pH 3-1 glycine-HCl on an Amicon XM-100 membrane and the fraction less than 100,000 daltons, "antigen fraction ", was assayed for TSTA activity. Sera from normal animals or animals bearing unrelated tumours gave minimal inhibition of binding. Sera from MC-1 tumour bearers gave significant inhibition of binding and an inhibition (Fig. 2) . This is strong evidence that the inhibitory material is MC-1 TSTA of less than 100,000 daltons.
On occasion, serum from unrelated tumour bearers, but never normal serum, gave cross-reacting inhibition of binding in the radioimmunoassay. This occurred when the labelled MC-1 TSTA ernployed in the assay was isolated from Sepharose coupled with unabsorbed MC-1 tumour immune y-globulin and the coupled antibody in the radioimmunoassay was likewise unabsorbed. Concentrations of MIC-1 TSTA in serum and lymph of rats In previous experiments (Thomson et al., 1973b) when studying the blood level of soluble TSTA in rats with the MC-1 sarcoma, it was shown that the serum of tumour bearers contained excess tumour antigen and immune complexes. In an attempt to obtain a higher yield of free tumour antigen in the serum these tumours were grown in rats given 500 rad of total body x-irradiation. A totally unexpected finding was that the sera from these animals gave evidence of circulating TSTA only at 21 days. In the present study this experiment was repeated. Rats were given 500 rad of total body x-irradiation followed by MC-1 tumour implantation. Serum from separate individual animals was drawn over 20 days and examined by radioimmunoassay for MC-1 TSTA. The values obtained are shown in Fig. 3 Seppala, 1972) has allowed new facets of human tumour immunology to be studied. Similarly, the technique described here for isolating and purifying tumour specific antigenic determinants of chemically induced tumours may offer the prospects of chemically defining these determinants and should facilitate the studY of their role in the host-tumour relationship. In addition, this method should be applicable to the isolation and purification of water-soluble human tumour antigens (GCutterman et al., 1972 ) capable of evoking a specific humoral immune response (Bias et al., 1972; Lewis et al., 1969) .
Since the solubilized TSTA retains its antigenicity, as determined by its ability to neutralize MC-1 tumour immune serum in the membrane immunofluorescence assay, the technique of affinity chromatography was chosen in order to achieve selective isolation and purification of the MC-1 tumour specific antigenic 384 CIRCULATING SOLUBLE TUMOUR ANTIGEN IN TUMOUR BEARERS moiety. Sepharose -antibody columns, unlike conventional techniques, are not dependent on unique physiochemical characteristics of the protein. They utilize immunoreactivity as the basis for separation and hence are particularly useful in conjunction with radioimmunoassay. Analysis by PAGE of the material isolated by affinity chromatography revealed a homogeneous component. This was not due to nonspecific interaction with the column matrix since other tumours (MC-3 and MC-11) did not yield a similar component. Futhermore, the 1251 labelled TSTA was specifically bound by MC-1 tumour immune y-globulin and the peak of activity on PAGE was eliminated whereas tumour immune sera from unrelated tumours did not alter the peak of activity.
By the initial isolation procedure of column chromatography, the MC-1 TSTA had a molecular weight estimated to be 40-50,000 (Thomson and Alexander, 1973a) . The MC-1 TSTA moiety purified by affinity chromatography has been examined by dodecyl S04 gel electrophoresis (Weber and Osborn, 1969) and by this method it has an apparent molecular weight of 44,000 ± 2000. The intact MC-1 TSTA moiety consists of peptide fragments linked by disulphide bonds since reduction with 2-mercaptoethanol yielded lower molecular weight fragments (unpublished observations).
The molecular weight estimate of 44,000 for the MC-1 TSTA antigen is close to that which has been reported previously for the intact papain solubilized HL-A and H-2 antigens (Sanderson, Welsh and Cresswell, 1971; Nathenson, Schwartz and Cullen, 1972) . It is also similar to the molecular weight of 43,000 which has recently been reported for the detergent solubilized HL-A antigens (Springer and Strominger, 1973) . With the similar H-2 antigenic system of mouse detergent solubilized material has also yielded molecular weights of about 43,000 (Nathenson et al., 1972) . Thus, if any fragment of the MC-1 TSTA antigen is left behind in the membrane on solubilization with papain this is likely to be relatively small.
A common tumour associated antigen was also isolated by affinity chromatography. On gel filtration its molecular weight was estimated as approximately 000 daltons and dodecyl S04 gel electrophoresis (unpublished observations) has shown a single band common to all tumours studied with a molecular weight of approximately 27,000 1 4000, indicating that the common tumour antigen probably exists as a dimer.
On the membranes of chemically induced tumours of rats and in early embryos a common tumour associated antigen was previously detected by membrane immunofluorescence with syngeneic tumour immune serum and it was termed " OEAI " (Thomson and (Thomson et al., 1969) and the normal HL-A antigens (van Rood, van Leuven and van Santen, 1970) . In earlier studies it was found that antibodies directed to the TSTA of chemically induced sarcomata could not be found in the serum of tumour bearing rats, whereas after removal of tumour by amputation of the leg, anti-TSTA antibodies could be detected in the serum by membrane immunofluorescence and by mixed haemabsorption (Thomson et al., 1973c) . The most simple explanation, that the antibody was absorbed in vivo by the tumour, was shown not to be an 385 important factor by measuring specific antibody in the thoracic duct lymph to the TSTA of sarcomata growing in the leg. Here, it was shown that specific antibody was low and rose sharply after excision of the tuimour (Thomson et al., 1 973c) . Consequently, we hypothesized that in the presence of a growing tumour soluble antigen escapes the tumour maAs and complexes with specific antibody to yield excess free soluble antigen and immune complexes (see also Currie and Basham, 1972; Currie and Gage, 1973 (Hellstrom, Hellstrom and Sjdgren, 1970; Baldwin, Embleton and Robbins, 1973a) . Also, limited clinical data show that blocking activity is seen primarily in patients with growing tumour and is frequently not found in patients who are symptom-free (Hellstrometal., 1971; Currie, 1973) . Further, other investigators have shown that soluble histocompatibility antigens, or tumour specific antigens in concentrations in excess of that required for optimal stimulation, are capable of specific abrogation of sensitized lymphocyte activity against target cells fn vitro (Brawn, 1971; Baldwin, Enmbleton and Price, 1973c) . Sjogren et al. (1971) have postulated that TSTA complexed with specific antibody may constitute the " blocking " material described by Hellstr6m et al. (1971) in the serum of cancer patients. As already indicated, specific antibody is produced during tumour growth (Thomson et al., 1973c) and this antibody complexes with soluble circulating antigen (Thomson et al., 1973b) . Moreover, no evidence was obtained to indicate that tumour cells in situ are coated with significant quantities of antibody (Thomson et al., 1973c) .
With excision of the tumour, in spite of the fact that the specific antibody levels increase, the animals are now capable of rejecting transplanted cells. Thus the difference in the tumour bearing and immune animal is not anti-TSTA antibody but the presence of circulating tumour antigen either free or complexed with specific antibody.
It seems probable, therefore, that the "blocking " effect represents an in vitro manifestation of a state of free soluble antigenic moieties. Our results suggest that the in vitro assay of " blocking " is interpreted most simply as a measure of circulating soluble tumour antigen.
The studies suggest that there are 3 mechanisms by which soluble TSTA is released from the membrane of tumour cells into the circulation: (1) spontaneous release through metabolic turnover of the cell surface; (2) during the course of tumour necrosis; (3) as a by-product of an immune reaction both cellular and humoral.
Circulating soluble TSTA in the size range of 10,000-100,000 daltons was detected infrequently if the rats into which the tumour has been implanted were immunosuppressed by whole body irradiation. It seems most likely, therefore, that an immune reaction, by attacking and damaging the tumour cells, enhances the release of excess free TSTA systemically. Prehn (1972) has postulated that the effect of immunity on target cells might be biphasic, that is, a mild reaction stimulates tumour growth although a strong one is cytotoxic. It may be further hypothesized that in the early evolution of tumours, when the immune response is incipient and therefore weak, direct lymphocyte and target cell interaction stimulates the tumour cell and intensifies the release of soluble tumour antigen. Acting locally, the soluble tumour antigen " inhibits " efficient lymphocyte cytotoxicity and enhancement of nascent tumour occurs. As the intensity of the immune response builds up and the lymphocytes become capable of a cytotoxic tumour effect, a larger mass of tumour presents itself to the host as a result of the previous stimulation of tumour growth. While a more cytotoxic tumour effect may occur, this again releases soluble cell surface antigen and produces feedback " inhibition " of lymphocyte " killer " function. The tumour mass progressively increases in size and at some critical stage there is a transition from local antigen excess to systemic antigen excess which overwhelms the host's immune response.
The phenomenon of feedback inhibition of soluble tumour antigen on lymphocytic " killer " function may explain why in most instances the tumour develops, metastasizes and finally kills the host instead of encountering resistance and being rejected eventually by an immune reaction of the host.
